Trial Profile
A phase I study of TKI258 and capecitabine in patients with advanced pancreatic cancer and treatment failure after first-line chemotherapy - CAPDOV
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Acronyms CAPDOV
- 17 Mar 2015 Status changed from recruiting to discontinued.
- 23 Jan 2015 Status changed from not yet recruiting to recruiting.
- 23 Apr 2013 New trial record